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CaspasesApoptosis is the process of programmed cell death. It is a ubiquitous, controlled process consuming cellular
energy and designed to avoid cytokine release despite activation of local immune cells, which clear the cell
fragments. The process occurs during organ development and in maintenance of homeostasis. Abnormalities
in any step of the apoptotic process are associated with autoimmune diseases and malignancies. Polycystic
kidney disease (PKD) is themost common inherited kidney disease leading to end-stage renal disease (ESRD).
Cyst formation requires multiple mechanisms and apoptosis is considered one of them. Abnormalities in
apoptotic processes have been described in various murine and rodent models of PKD as well as in human
PKD kidneys. The purpose of this review is to outline the role of apoptosis in progression of PKD as well as
to describe the mechanisms involved. This article is part of a Special Issue entitled: Polycystic Kidney
Disease.stic Kidney Disease.
ll rights reserved.© 2011 Elsevier B.V. All rights reserved.1. Introduction
Autosomal dominant polycystic kidney disease (ADPKD) is the
most common life threatening hereditary disease in the USA [1]. It
affects about 1:500 people. Approximately 50% of people with ADPKD
develop renal failure. ADPKD accounts for about 5–10% of end-stage
renal disease requiring dialysis and renal transplantation [1]. PKD1
encodes polycystin-1 and mutations in this gene account for about
85% of cases of ADPKD, while mutations in PKD2 encoding polycystin-
2 are responsible for 10–15%. Autosomal recessive polycystic kidney
disease (ARPKD) affects 1 in 20,000 live births and is an important
cause of renal and liver-related morbidity and mortality in neonates
and infants [2,3]. This disease is caused by mutations in the polycystic
kidney and hepatic disease gene 1 (PKHD1) which encodes ﬁbrocys-
tin/polyductin (FC1), a 500-kDa type I membrane protein expressed
in the primary cilium and plasma membrane of renal and bile duct
epithelial cells, as well as in the extrahepatic biliary duct [4,5].
Abnormalities of both cyst-lining epithelium and the noncystic
tubular epithelium contribute to cyst formation in the kidney and
are key to the disease progression.
The following molecular abnormalities of the tubular epithelium
lining the cysts have been extensively described: (1) abnormal ﬂuid
secretion, (2) abnormalities of cell–matrix interactions, (3) altera-tions in polarity of membrane proteins, (4) abnormal ciliary function,
and (5) disturbance in the balance between tubular cell proliferation
and apoptosis [6].
Apoptosis is central to normal kidney development and has been
implicated in kidney diseases of various origins, including PKD [7,8].
The cystic epithelia in both ADPKD and ARPKD display dedifferen-
tiated cells with polarization defects, high rates of division and
apoptosis [8–12].2. Mechanisms of apoptosis
Apoptosis is the Greek word for “falling off”, such as petals falling
off a plant. The term was coined by Kerr, Currie, and Wyllie in 1972
[13], although the principle of apoptosis was ﬁrst described as early as
1842 by the German scientist Carl Vogt. The term expresses the
understanding that programmed cell death is a physiologic and active
process. Apoptosis is tightly regulated to ensure safe elimination of
defective cells while sparing adjacent normal cells. The decision for a
cell to die is based on the balance between intracellular pro- and
antiapoptotic factors, i.e., the caspases and intracellular inhibitors of
apoptosis, respectively. The latter can be roughly divided into two
separate families: 1) the inhibitors of apoptosis proteins (IAPs) and 2)
several members of the Bcl-2 family, which are further discussed
below. The process of apoptosis involves cell volume reduction,
blebbing and loss of cell membrane asymmetry and cell–cell contacts.
It leads to nuclear fragmentation, chromatin condensation, and
internucleosomal DNA fragmentation [14]. Cells undergoing apopto-
sis have been described as performing the “Dance of Death”, or Danse
Macabre, which is not to be confused with the late-medieval allegory
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of the level of cellular activity apoptosis requires. Apoptosis takes only
about one to six hours and occurs about 50 to 70 billion times per day
in an adult person. The loss of membrane asymmetry leads to
exposure of phosphatidylserine at the surface of the cell, which in turn
is a strong signal for phagocytosis [16].
Caspases are cysteine proteases that can be divided into two
groups, (i) mediators of apoptosis and, (ii) mediators of inﬂammation
(Table 1). The apoptotic caspases are subdivided into initiating and
executing caspases [17]. Caspases are present in the cytosol in an
inactive pro-form [18]. They are activated to fully functional proteases
by two cleavage steps. The ﬁrst divides the chain into large and small
caspase subunits, and the second removes the N-terminal prodomain
[18]. Since proteolytic cleavage generates the mature caspases, one
way in which these enzymes are activated is via the action of
proteases, including other caspases. Thus, caspases can function in an
activation cascade. Caspases-8 and -9 trigger apoptosis by activating
the executing caspases [19]. Caspase-3 cuts off contacts with
surrounding cells, reorganizes the cytoskeleton, shuts down DNA
replication, interrupts splicing, disrupts the nuclear structure, marks
the cell for phagocytosis and disintegrates the cell into apoptotic
bodies [20–23].
Cells contain natural inhibitors of caspases. These inhibitors of
apoptosis proteins (IAPs) were ﬁrst identiﬁed in baculovirus and
subsequently found in human cells (XIAP, c-IAP1, and c-IAP2) [24,25].
IAPs are recognized by the presence of a ~70 amino acid BIR
(baculovirus IAP repeat), a zinc-ﬁnger-fold present at least once in
each familymember [26]. IAPs can act as direct inhibitors of caspases-3
and -7, and are able to suppress the activation of caspases-8 and -9
[25,27,28]. The eight IAPs in humans contain one to three BIRs,
typically arranged at the N-terminus of the protein. Compared with
other IAPs, survivin is structurally unique. It is the smallest mam-
malian IAP, containing a single BIR and a long C-terminal α-helix, but
no other identiﬁable protein domain. Structural data suggest that
survivin forms a stable homodimer in solution [29]. Survivin is im-
plicated in both control of apoptosis and regulation of cell division and
it was shown that phosphorylated survivin can interact with and
inhibit caspase-9 [30].
Two major intracellular apoptotic pathways have been described
(Fig. 1); In the mitochondrial or “intrinsic” pathway, stress-induced
signals act via B cell CLL/lymphoma-2 (Bcl-2) proteins to cause
cytochrome c release from mitochondria due to mitochondrial outer
membrane permeabilization. Cytochrome c binds to the cytosolic
protein, apoptosis protease-activating factor-1 (APAF-1) in theTable 1
Caspases are divided into two sub-groups: caspases involved in the inﬂammatory
process and those involved in the apoptotic process. The apoptotic caspases are further
subdivided into initiating and executing caspases. Initiating caspases are activated by
either external stimuli via activation of extracellular death receptors or by loss of the





















Caspase-12 √presence of ATP, forming the apoptosome, which recruits and
activates caspase-9. Active caspase-9 in turn recruits and activates
procaspase-3 and -7. The post-mitochondrial events are tightly
regulated by heat shock proteins and IAPs [31,32]. Bcl-2 and its
relatives are functionally classiﬁed as either antiapoptotic or proa-
poptotic. Most cells express a variety of antiapoptotic and proapopto-
tic Bcl-2 proteins, and the regulation of their interactions dictates
survival or commitment to apoptosis. The main effector proapoptotic
Bcl-2 members are Bcl-2 antagonist killer 1 (Bak) and Bcl-2-
associated x protein (Bax) [33]. Upon activation, Bak and Bax homo-
oligomerize into proteolipid pores within the outer mitochondrial
membrane (OMM) to promote mitochondrial outer membrane
permeabilization. Antiapoptotic Bcl-2 proteins are generally integrat-
ed within the OMM. Bcl-2-related gene A1, Bcl-2, Bcl-2-related gene,
long isoform (Bcl-xL), Bcl-w, and myeloid cell leukemia 1 are the
major members of the antiapoptotic Bcl-2 repertoire and preserve
OMM integrity by directly inhibiting the proapoptotic Bcl-2 proteins
[34,35].
In the “extrinsic” pathway, the binding of a ligand to its death
receptor at the surface of the cell recruits an adaptor protein that in
turn recruits and cleaves procaspase-8, which then leads to activation
of executing caspases [36].
Apoptosis can be detected by various molecular methods.
Morphological cellular changes remain a gold standard for apoptosis
identiﬁcation. In cell culture, nuclear chromatin staining with a cell-
permeable, DNA-binding ﬂuorochrome is a simple, yet accurate
method [37]. DNA fragmentation can be demonstrated by terminal
transferase-mediated dUTP nick end-labeling (TUNEL) [38] (Fig. 2).
Apoptosis is also associated with an outward movement of phospha-
tidylserine (PS) in the plasma membrane as a consequence of loss of
ATP [39]. Annexin V is a Ca2+-dependent phospholipids-binding
protein with high afﬁnity for PS and can be coupled to a ﬂuorochrome,
thus allowing detection of apoptotic cells [40]. Alteration of
mitochondrial integrity such as occurs during activation of the
intrinsic apoptotic pathway, can be measured in various ways,
including production of reactive oxygen species, translocation of
soluble inter-membrane proteins, and loss of mitochondrial mem-
brane potential [41,42].
3. Role and mechanisms of apoptosis in PKD
In PKD, abnormal proliferation in tubular epithelial cells plays a
crucial role in cyst development and/or growth [43]. Kidneys from
patients with ADPKD have high levels of apoptosis as well as cellular
proliferation [44]. The SBM mouse is a transgenic murine model that
bears similarities to human adult ADPKD. It carries a fusion gene
including the c-myc coding region, the β-globin promoter and the
simian virus 40 (SV40) enhancer, which is expressed at high levels in
the renal tubular epithelium [45]. These animals reproducibly develop
renal morphological and functional alterations characteristic of PKD,
and die of renal failure. In this mouse model, there is a 10–100 fold
increase in both apoptosis and proliferation [46,47]. Increased
apoptosis and proliferation occur early in the course of the disease
and precede cystogenesis in SBM mice [48]. Another frequently used
model of ADPKD is the Han:SPRD rat [49]. It is derived from a
spontaneous mutation in the Sprague–Dawley strain and inherits the
disease in an autosomal dominant fashion [50]. Heterozygous animals
of this strain develop slowly progressive renal cystic disease, whereas
homozygous rats develop massive renal enlargement leading to early
death [51]. This rodent model is considered highly suitable to study
initial processes in tubular cystic transformation [52]. In Han:SPRD rats
fed soy protein, the observed improved renal function and decreased
cyst formation are accompanied by decreases in both tubular cell
proliferation and apoptosis [53].
Apoptosis in PKD seems to act like a double-edged sword. The
literature can be split into two groups: one accusing apoptosis of
Fig. 1. Intracellular pathways of apoptosis. External apoptotic stimuli (extrinsic) lead to activation of caspase-8, while mitochondrial damage (intrinsic) leads to activation of
caspase-9. Both pathways converge to activation of executing caspases. Activation of executing caspases is considered the point of no return. Both apoptotic pathways can be
inhibited by IAPs. The intrinsic pathway can also be inhibited by antiapoptotic members of the Bcl-2 family of proteins and activation of caspase-8 in the extrinsic pathway can be
inhibited by c-FLIP.
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claiming that inducing apoptosis slows down disease progression
[54]. Clearly, both epithelial cell apoptosis and proliferation are
dysregulated in ADPKD and may represent a general mechanism for
cyst growth and tissue remodeling [1,44]. By applying simple logic, it
is evident that apoptosis per se cannot be the main culprit for PKD,
because polycystic kidneys are massively enlarged and if apoptosis
were to be the predominant feature, it would be expected that the
kidneys would eventually involute, such as is the case in the majority
of congenital dysplastic kidneys [55]. It seems that it is an imbalance
between proapoptotic and pro-proliferative factors, rather than the
absolute expression levels that play a critical role in the development
of cystic kidney disease [56]. This imbalance leads to aberrant cell
cycle progression in a similar fashion to cancer, such that PKD has
been labeled “neoplasia in disguise” [57]. Cancers are generally
characterized by suppression of apoptosis and the goal of cancer
therapy is to induce apoptosis in malignant cells [58]. In the Bcl-2
transgenic mouse model, Bcl-2 was retrovirally introduced into the
bone marrow of wild-type mice or transgenic mice overexpressing
the c-myc oncogene (Em-myc) [59]. Bcl-2 cooperated with c-myc to
promote transformation of B cell precursors [60]. Although develop-
mentally normal, the adult Bcl-2−/− mouse displays thymus and
spleen involution, polycystic kidney disease, and hypopigmented hair
due to increased apoptosis. Mice deﬁcient in the proapoptotic Bcl-2
gene have hyperproliferation as well as apoptosis with renal cysts
[46,61]. Transgenic expression of human Bcl-2 in all organs except the
kidneys resulted in early death due to renal failure due to PKD in this
mouse model [62]. However, in an in vitro model of PKD, apoptosis
was shown to be causally linked to cyst formation [63]. Apoptosis was
essential for Madin–Darby canine kidney (MDCK) cell cyst cavitation incollagen type 1 matrix. Cystogenesis in this system was inhibited by
overexpression of the antiapoptotic gene, Bcl-2. The timing between
apoptosis and proliferation is also a chicken-or-egg type of controversy.
While the latter seems to have been solved as of recent [64], whether
apoptosis is secondary to proliferation or vice versa, is still a subject of
debate. It seems that the controversy in the PKD literature is generated
by several confounding factors in the experimental designs of the
studies: (i) animal models versus human PKD, (ii) early versus late
disease, (iii) cyst-lining epithelium versus normal-appearing tubules,
and (iv) primary end-points being decreased cyst formation or
regression in kidney size. In a seminal paper by David Woo, apoptosis
was detected in kidneys of humanswith ADPKD regardless of degree of
renal dysfunction, but not in normal kidneys. Particularly, apoptosiswas
detected in normal-appearing, noncystic tubules suggesting that it may
be associated with the progressive loss of normal nephrons in PKD [8].
Overall, however, the scientiﬁc community agrees that dysregulation of
apoptosis contributes to the progression of ARPKD, ADPKD, juvenile
nephronophthisis, and dysplastic renal disease associated with cyst
formation in both humans and animalmodels [8,44,65,66]. In summary,
there is much evidence that apoptosis is abnormally persistent in PKD
and may result in cyst formation. The following are the main points
suggesting a pathophysiological role for apoptosis in PKD: 1) Tubular
cell apoptosis occurs inmost animalmodels of PKD and in kidneys from
humans with PKD. 2) Mice overexpressing the proto-oncogene c-myc
(SBM mice), mice lacking the transcription factor AP-2β, and Bcl-2
deﬁcientmicehave increased apoptosis and develop cysts in the kidney.
3) Apoptosis is essential for MDCK cell cyst cavitation in collagen type 1
matrix; cystogenesis in this system is inhibited by overexpression of the
antiapoptotic gene, Bcl-2, and tubule formation is induced with
expression of PKD1, and 4) a direct cause and effect relationship
Fig. 2. In situ hybridization using terminal transferase-mediated dUTP nick end-labeling (TUNEL) method in a kidney from a patient with early-stage ADPKD (B), normal age-
matched kidney (A), a fetal ARPKD kidney (F), and an age-matched fetal kidney (E). Note the lack of apoptosis in the normal adult kidney and the relative abundance in the
nephrogenic zone of the normal fetal kidney. Long arrows in (B) point on sporadic apoptotic cells in cyst-lining epithelia of small cysts and short arrows point on apoptosis in
epithelium of normal-appearing tubules (D) depict an area within a section from an end-stage ADPKD kidney (patient is on renal replacement therapy), demonstrating hyperplastic
cyst-lining epithelium, accompanied by extensive apoptosis.
Reprint from Goilav et al. Pediatr Nephrol 2008, with permission.
1275B. Goilav / Biochimica et Biophysica Acta 1812 (2011) 1272–1280between apoptosis and cyst formation is demonstrated by a study in
Han:SPRD rats in which caspase and apoptosis inhibition with a pan-
caspase inhibitor decreases apoptosis and proliferation in cystic and
noncystic tubules, inhibits renal enlargement and cystogenesis, and
attenuates the loss of kidney function. [1,8,46,48,63,67–70]On the other
hand, there is also evidence that increased apoptosis in tubular cellsmay
be associated with decreased cyst formation. For example, Pax2
deﬁcient mice that have increased apoptosis, were backcrossed into
congenital polycystic kidney (cpk) mice have increased renal apoptosis
yet less cystic disease [44,46–48,53,71,72].4. Implications of PKD1, PKD2, and PKHD1 in control of apoptosis
A study implicated PKD1 in the regulation of apoptosis, proliferation
and cyst formation. Expression of human PKD1 in MDCK cells slows the
rate of proliferation and is protective fromapoptosis [70]. Also, there is a
tendency towards tubule formation rather than cystogenesis [70]. The
gene may therefore be directly involved in the regulation of both
apoptosis and proliferation pathways, allowing cells to enter a
differentiation pathway that results in tubule formation. This study
provided evidence that (i) polycystin-1 inhibits apoptosis and (ii) that
increased apoptosis is associated with cyst formation in MDCK cells.
Another evidence for a direct role of polycystin-1 in apoptosis regulation
was provided by a study demonstrating an interaction between
polycystin-1 and nephrocystin-1 that is required for polycystin-1-
induced resistance to apoptosis [73]. Recent studies also demonstrated
that polycystin-1 expression levels controlled G-protein-stimulated
apoptosis in that polycystin-1 was able to inhibit apoptosis [74] and aspeciﬁc binding site between polycystin-1 and the G protein was
detected, which could act as a potential new pharmacological target
[75].
In a mouse model of ADPKD due to PKD2 mutations, both mitotic
and apoptotic indices were increased compared with wild-type
controls. As a matter of fact, apoptotic indices increased gradually
with disease progression [76].
Knockdown of PKHD1 by short hairpin RNA interference in IMCD
cells results in disrupted normal tubulo-morphogenesis and increased
apoptosis as well as proliferation [77]. Nuclear factor kappa B (NFκB)
is a transcription factor, which plays a pivotal role in promotion of cell
proliferation and inﬂammation, as well as suppression of apoptosis
[78,79]. siRNA-induced knockdown of PKHD1 in human kidney cells
results in an increase in apoptosis [80]. NFκB inactivation is required
for the suppression of caspase-3 activity and reduction of cell death in
FC1-depleted cells, thus showing that NFκB may play a proapoptotic
role in polycystic cells. Hence, FC1 is involved in the control of
apoptosis through themodulation of NFκB [80]. Cell features observed
in FC1-depleted cells are consistent with previous ﬁndings showing
increased apoptosis and reduced proliferation in mouse renal tubular
IMCD cells after PKHD1-silencing [77].5. Caspase activation
Increased rates of apoptosis and increased caspase-3 activity have
been demonstrated in kidneys from ARPKD rodent models [81,82].
Apoptosis is localized primarily to the interstitiumwith little evidence
of cell death in cyst epithelium or noncystic tubules. A marked
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Han:SPRD rat [56,83]. In this model, pan-caspase inhibition reduces
tubular apoptosis and proliferation and slows cystic kidney disease
progression and in a mouse model of ARPKD, targeted caspase-3 gene
deletion prolongs survival [68,84]. In human PKD kidneys, the
initiator caspase-8 and the executing caspase-3 are activated early
in ADPKD, before the patient has progressed to ESRD and is mainly
found in normal-appearing tubules [12]. Hence, apoptosis in normal
tubules further contributes to the progression of loss of renal function
in ADPKD. The extrinsic pathway does not seem to play a role in
human ARPKD, although there is increased expression of caspase-3
[12]. In homozygous cystic kidneys of Han:SPRD rats, activation of
both the intrinsic and extrinsic pathway can be detected. However, no
differences in FasL mRNA are seen, suggesting that the extrinsic
pathway is independent of that particular ligand [83].
6. Downregulation of inhibitors of apoptosis
Bcl-2 deﬁcient mice have increased apoptosis in the kidneys, and
renal failure results from severe PKD characterized by dilated
proximal and distal tubular segments and hyperproliferation of
epithelium and interstitium [46,71,72]. Alternatively, increased Bcl-
2 expression has been demonstrated in animal models of both ARPKD
and ADPKD [44,56,82]. High levels of Bcl-2 prevent apoptosis as well
as cyst formation in MDCK cells [63]. In Han:SPRD rats, apoptotic cells
are signiﬁcantly increased in two-week mutant animals, compared to
normal littermate controls. Decreased expression of Bcl-xL coincides
with increased caspase-3 activity at two weeks of age while
expression of Bcl-2 increases at six weeks of age. Proapoptotic Bax
and Bad expression was unchanged at two weeks of age in both
heterozygous and homozygous rat kidneys. This study demonstrates
that dysregulation of the balance between pro- and antiapoptotic Bcl-
2 family members, speciﬁcally a downregulation of antiapoptotic Bcl-
xL, correlates with increased apoptosis in the kidneys [56].
The IAP survivin is increased in renal cancers and also in two-week
old homozygous Han:SPRD rat kidneys in association with activation
of caspase-9 and increased apoptosis [67].
Cellular (FADD)-like interleukin-1β-converting enzyme inhibitory
protein (c-FLIP) is structurally related to caspase-8, but its caspase
domain is altered, rendering it inactive. It is therefore a natural
inhibitor of activated caspase-8. It is present in normal human kidney
tissue, but undetectable in small cysts and normal-appearing tubules
in human ADPKD kidney tissues from pre-dialysis patients [85]. c-FLIP
was detectable in large cysts from end-stage ADPKD kidneys.
Essentially, the expression pattern of c-FLIP was a mirror image of
the expression of caspase-8. Hence, c-FLIP may be a candidate
involved in the modulation of proliferation and apoptosis in ADPKD.
7. Proto-oncogenes
Abnormal expression of proto-oncogenes, in particular, c-mycmay
also contribute to abnormalities in proliferation and apoptosis,
leading to cyst development. In both murine ARPKD and human
ADPKD kidneys, c-myc is overexpressed in cystic tissue [44,86,87] and
is associated with a marked increase in both tubular cellular
proliferation and apoptosis. Overexpression of c-myc is thought to
play a role in the dysregulation of both proliferation and apoptosis in
ADPKD [48,88,89]. In addition, c-myc antisense oligonucleotides
ameliorate cystic kidney disease in a murine ARPKD model [89]. The
pathway of c-myc induced apoptosis is thought to be mediated by
caspase-9 and caspase-3 [90].
8. Cell cycle abnormalities
Two key classes of regulatory molecules, cyclins and cyclin-
dependent kinases (CDKs), determine progression through the cellcycle [91]. Most genes encoding cyclins and CDKs are conserved
among all eukaryotes [92]. Cyclins form the regulatory subunits and
CDKs the catalytic subunits of an activated heterodimer. CDKs are
constitutively expressed in cells whereas cyclins are synthesized at
speciﬁc stages of the cell cycle, in response to various molecular
signals [93].
Two families of genes, the cip/kip family and the INK4a/ARF
(Inhibitor of Kinase 4/Alternative Reading Frame) encode CDK
inhibitors. These genes are considered to be tumor suppressors [94].
The cip/kip family includes the genes p21, p27, and p57. They halt cell
cycle in G1 phase and inactivate, cyclin-CDK complexes. p21 is
activated by p53. The INK4a/ARF family includes p16INK4a, which
binds to CDK4 and arrests the cell cycle in G1 phase, and p14arf, which
prevents p53 degradation.
Abnormal cell cycle regulation has been suggested to contribute to
PKD. Polycystin-1 increases expression of p21, and p21 is decreased in
human and a rat model of PKD [95,96]. These ﬁndings are consistent
with the observed augmentation of both cell proliferation and
apoptosis in this disease.
9. Therapeutic interventions implicating apoptotic pathways
9.1. Mammalian target of rapamycin (mTOR)
The mammalian target of rapamycin (mTOR) pathway is an
evolutionarily conserved pathway that transmits cell growth and
survival signals in cells. It senses the availability of nutrients and
growth factors in the environment and responds by signaling for
cell growth and division [97]. The mTOR pathway has become of
interest in the pathophysiology of PKD because it also integrates
signals from growth factors (including EGFR) and G-protein
coupled receptors (which generate cAMP) [98,99]. Mutated TSC1
and TSC2 genes cause tuberous sclerosis, a disease in which renal
cystic lesions may accompany the more classical renal angiomyo-
lipomas [100] and TSC1/2 mutations are associated with upregulate
mTOR signaling. The TSC2 and PKD1 genes lie adjacent to each other
on human chromosome 16p13.3 and the cytoplasmic tail of
polycystin-1 interacts with mTOR. This sparked the interest for a
possible mTOR activity in PKD. In a variety of animal models, as well
as in human ADPKD and ARPKD cyst-lining epithelia, expression of
phospho-mTOR and p70S6K is increased [101]. Indeed, in the
absence of polycystin-1, activation of mTOR results in increased cell
growth. Inhibition of the mTOR pathway reverses renal cystogene-
sis in PKD and has been associated with an increased rate in
apoptosis in vitro [102]. Rapamycin is an immunosuppressive drug
that inhibits mTOR and is used to prevent transplant rejection.
Rapamycin and a related drug everolimus were evaluated in the
Han:SPRD rat [103,104]. Inhibition of mTOR signiﬁcantly slows cyst
growth in this model. Other studies have tested the efﬁcacy of
rapamycin in three non-orthologous mouse models of PKD,
Tg737orpk/orpk mice (mutation in the ciliary protein Polaris),
bpk mice, and kidney-speciﬁc BHD (gene mutated in patients with
Birt–Hogg–Dubé syndrome) mutant mice [101,105]. These studies
also revealed signiﬁcant improvement in cyst size and azotemia
compared to control animals. In a retrospective study, Shillingford
examined a small group of patients who had undergone kidney
transplantation for ESRD due to ADPKD and retained their native
cystic kidneys [101]. In four patients who received rapamycin as
part of their post-transplant immunosuppression, the volume of the
native cystic kidneys was reduced by 24% compared to 8.6% in three
patients treated with other immunosuppressants. The change in
kidney size was signiﬁcantly different between the rapamycin and
non-rapamycin groups. Another retrospective study by Qian de-
monstrated that rapamycin decreased the size and number of liver
cysts but failed to show a beneﬁt on kidney cysts [106]. Nonethe-
less, these results were encouraging enough to lead to prospective
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everolimus [107] and sirolimus [108] in patients with early ADPKD.
However, neither of the studies demonstrated slowing of the
disease progression, despite a slowing of the increase in kidney
volume. The lack of demonstrable effects may have been due to a
relatively short follow-up period (2 years and 18 months, respec-
tively). Another caveat to the studies was that both sirolimus and
everolimus had signiﬁcant side effect proﬁles and the patients did
not tolerate what was considered a therapeutic dose.
9.2. Cyclin-dependent kinase inhibitors
The CDK inhibitors, both endogenous (p21) and synthetic (ros-
covitine), have shown promise in the treatment of cancer [10], and
more recently, of ADPKD [109]. Germino was the ﬁrst to suggest a
relationship between p21 and PKD by showing that p21 is induced
polycystin-1 [95]. Increased apoptotic loss of renal tissue was found
in subsequent studies in the presence of the reduced levels of p21
[110–112]. Roscovitine, an inhibitor of cyclin-dependent kinases was
administered to two non-orthologous mouse models of recessive
PKD, jck mice and cpk mice and resulted in arrest of cyst growth [10].
Intermittent administration of roscovitine has a long-lasting anti-
cystic effect [113]. At high concentrations, roscovitine results in
caspase-3 activity being signiﬁcantly increased from control cells.
Low doses of roscovitine likely induce minor repairable damage to
cells, which in turn cause activation of ATM, p53, and p21, and
activate the Akt pathway, which prevents cells from entering the
apoptosis pathway rather than the survival pathway. As a result, cells
enter the permanent cell cycle arrest stage, or replicative senescence,
which is an ideal result for a potential PKD therapeutic. That low-dose
roscovitine induces senescent markers in association with p21 aug-
mentation is consistent with the known role of p21 in causing repli-
cative senescence and its absence in avoiding this fate, and suggests
that these events are mechanistically related [114–117]. This state of
irreversible cell cycle arrest has the potential to beneﬁcially modulate
the aberrant cell proliferation seen in PKD [118]. Recent studies
revealed that the p53 pathway monitors the mTOR pathways; in
response to stress, the p53 pathway negatively regulates the IGF-1/
AKT and mTOR pathways to shut down cell growth and division
[119].
9.3. Caspase inhibition
Heterozygous Han:SPRD rats treated with the pan-caspase inhibitor
IDN-8050 or vehicle for ﬁve weeks [68] develop the following
phenotypic changes: (1) decreased apoptosis and proliferation in cystic
andnoncystic tubules, (2) inhibited renal enlargement and cystogenesis
and (3) attenuated loss of kidney function [68]. Caspase inhibition may
impede a commonpathway for both apoptosis and proliferation and the
decrease in proliferation may be beneﬁcial in reducing cyst formation.
Anothermodel of PKD, the cpkmouse, dies fromrenal failure andPKDat
a mean age of 32 days. Complete deﬁciency of caspase-3 prolongs the
life of the cpk mouse [67].
10. Conclusion
The heightened cellular proliferation and apoptosis observed in
SBM mice and human ADPKD resemble the process occurring during
renal organogenesis [120]. Cystic epithelia in PKD are characterized by
mispolarization of channels and cell surface receptor reminiscent of a
fetal phenotype [121]. During renal development, apoptosis and
proliferation are the main mechanisms by which extensive remodel-
ing of the kidney structures occurs. Experiments interfering with
these processes result in dysplastic, non-functioning kidneys [122]. It
is unclear what the underlying cause of the acquisition of a fetal
phenotype in cystic tubular epithelial cells is. However, a studycomparing pathways of apoptosis in adult and fetal kidneys as well as
human PKD kidneys failed to show similarities between nephrogen-
esis and PKD [12]. Therefore, the dedifferentiation occurring in cystic
epithelial cells is not simply a “step backwards”, but likely a reaction
to the environment encountered in PKD kidneys. Analysis of cyst ﬂuid
has revealed the presence of multiple cytokines, among them are TGF-
β, TGF-α, and EGF [123,124]. These cytokines are closely involved in
apoptosis, proliferation, and differentiation. They are also cytokines
encountered in inﬂammatory states, such as ischemia-reperfusion
injury. The consequence to ischemia of renal tubular epithelial cells is
clinically referred to as acute tubular necrosis (ATN), which is a partial
misnomer, since tubular epithelial cells do not just die due to necrosis,
but also undergo apoptosis [125]. The cells slough off the tubular
basement membrane and can be found in the urinary sediment of the
patient [125]. Once a favorable environment has been restored in the
kidney, dedifferentiated tubular cells migrate back onto the tubular
basement membrane and proliferate in order to restore tubular
transport functions. The phenotype of the dedifferentiated cells is
similar to cyst-lining epithelial cells in that they are not terminally
differentiated and that they have a large proliferative capacity.
Nonetheless, despite the similarities between cyst-lining epithelial
cells and tubular epithelial cells involved in regeneration, in ATN, once
the tubular basement membrane is covered with cells and the cell–
cell junctions as well as the cell–matrix adherence have been restored,
terminal differentiation occurs, and proliferation stops. This is not true
for PKD.Whether this phenomenon is due to ongoing cytokine release
and ischemia, is beyond the scope of this review, but has been
discussed elsewhere in the past [126]. Evidently, mechanisms
governing apoptosis and proliferation in PKD seem to be of a different
nature than the ones involved in nephrogenesis or ischemia-
reperfusion injury.
The precise pathways that link apoptosis and proliferation in PKD
remain to be determined. There are two lines of evidence for a
common pathway of apoptosis and proliferation involving adhesion-
dependent control of apoptosis and overexpression of the proto-
oncogene c-myc. Changes in cell shape and loss of cell to cell adhesion
during apoptosis may stimulate surrounding cells to proliferate [127].
Theoretically, in PKD, loss of tubular cells by apoptosis may initiate
proliferation of neighboring tubular cells. In this case, both apoptosis
and proliferation would be seen in the same cyst and caspase
inhibition would attenuate both processes. Advances in understand-
ing of the apoptotic pathways have led to the development of drugs,
which suppress apoptosis. However, apoptosis in PKD, beyond its role
in cyst cavitation, contributes to the loss of renal tissue and may be
responsible for the progressive deterioration of renal function that
occurs in patients with ADPKD [8]. On the other hand, however,
apoptosis can be viewed as the last line of defense against oxidative or
other form of DNA damage, thus reducing the risk for neoplastic
transformation and explaining the lack of a convincingly increased
risk for renal cell carcinoma in this condition despite the high rate of
epithelial cell proliferation. Therefore, elucidation of the mechanisms
responsible for the coupled stimulation of cell proliferation and
apoptosis in ADPKD may provide opportunities for interventions that
avoid the potential risk of selectively inhibiting apoptosis alone.
Exciting times are awaiting us in the near future.
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